Communiqués Coya Therapeutics, Inc.

Actions

COYA

US22407B1089

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
4,810 ^USD	+1,69%		-5,31%	-17,07%

15/09	Coya Therapeutics recrute son 100ème participant pour l'essai de Phase 2/3 ALSTARS sur le COYA 302 dans le traitement de la SLA	CI
08/09	Coya Therapeutics annonce la publication d'une étude préclinique démontrant les effets immunomodulateurs combinés de COYA 303 dans un modèle reconnu d'inflammation périphérique et du SNC	CI

Communiqués

15/09	Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS	BU
08/09	Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation	BU
11/08	Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update	BU
18/06	Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting	BU
15/06	Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease	BU
08/06	Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase	BU
27/05	Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit	BU
12/05	Investor Presentation (05/12/2026 00:00:00)	PU
12/05	Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update	BU
12/05	Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)	BU
01/05	Investor Presentation (05/01/2026 00:00:00)	PU
09/04	Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS	BU
02/04	Investor Presentation (04/02/2026 00:00:00)	PU
02/04	Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director	BU
18/03	Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy	BU
16/03	Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results	BU
01/03	Investor Presentation (03/01/2026 00:00:00)	PU
11/02	Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis Drug Development, Patient Landscape, and Ongoing Clinical Trial	AQ
10/02	Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial	BU
02/02	Investor Presentation (02/01/2026 00:00:00)	PU
02/02	Coya Therapeutics Announces $11.1 Million Private Placement	AQ
30/01	Coya Therapeutics Announces $11.1 Million Private Placement	BU
20/01	Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders	BU
08/01	Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients	BU
06/01	Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal Dementia	AQ